Sarah S. Mougalian
YOU?
Author Swipe
View article: Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021 Open
Importance Advances in treatment of metastatic breast cancer (MBC) led to changes in clinical practice and treatment costs in the US over the past decade. There is limited information on current MBC treatment sequences and associated costs…
View article: Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study
Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study Open
Background Expert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach the wider oncology community. Objective Using an oncologis…
View article: Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis Open
Purpose: This meta-analysis provides a longitudinal assessment of depression and cognitive impairment induced by taxane-based chemotherapy in women with breast cancer after 6 months of treatment. We highlighted the incidence and prevalence…
View article: Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy Open
Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in pati…
View article: Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With<i>ERBB2</i>(<i>HER2</i>)–Positive Breast Cancer
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With<i>ERBB2</i>(<i>HER2</i>)–Positive Breast Cancer Open
These results suggest that neoadjuvant THP followed by adjuvant H for patients with pCR or followed by adjuvant DDAC plus T-DM1 for patients with residual disease was associated with the highest health benefits and lowest costs for women w…
View article: Observational Study of Clinical Outcomes of Eribulin Mesylate in Metastatic Breast Cancer After Cyclin-Dependent Kinase 4/6 Inhibitor Therapy
Observational Study of Clinical Outcomes of Eribulin Mesylate in Metastatic Breast Cancer After Cyclin-Dependent Kinase 4/6 Inhibitor Therapy Open
Aim: To examine the effectiveness of eribulin mesylate for metastatic breast cancer post cyclin-dependent kinase inhibitor (CDKi) 4/6 therapy. Materials & methods: US community oncologists reviewed charts of patients who had received eribu…
View article: A novel tool to monitor adherence to oral oncolytics: a pilot study
A novel tool to monitor adherence to oral oncolytics: a pilot study Open
Background: Non-adherence is an important issue in cancer care as more oral cytotoxic and targeted agents become available. Although oral therapies may be more convenient for patients, measuring and optimizing adherence is challenging. The…
View article: Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ
Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ Open
The use of sentinel lymph node biopsy (SLNB) for ductal carcinoma in situ (DCIS) is controversial. Using population-cohort data, we examined whether SLNB improves long-term outcomes among patients with DCIS who underwent breast-conserving …
View article: Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis Open
Background: Literature suggests that Oncotype DX (ODX) is cost-effective. These studies, however, tend to ignore clinical characteristics and have not incorporated population-based data regarding the distribution of ODX results across diff…
View article: Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the <scp>US</scp> community oncology setting
Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the <span>US</span> community oncology setting Open
Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials ( RCT s). This study examined characteristics and outcomes of metastatic triple‐negative bre…
View article: Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors
Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors Open
Background: Guidelines recommend annual mammography after curative-intent treatment for breast cancer. The goal of this study was to assess contemporary patterns of breast imaging after breast cancer treatment. Methods: Administrative clai…
View article: Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer
Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer Open
Background: Despite evidence on large variation in breast cancer expenditures across geographic regions, there is little understanding about the association between expenditures and patient outcomes. Objectives: To examine whether Medicare…
View article: Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making Open
Purpose: The 21-gene recurrence score (RS) assay is used to help formulate adjuvant chemotherapy recommendations for patients with estrogen receptor–positive, early-stage breast cancer. Most frequently, medical oncologists order RS after s…
View article: Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study Open
Our data suggest that RT is associated with a significant risk of subsequent MN among older breast cancer survivors, though the absolute risk increase is very small. These findings suggest the benefits of RT outweigh the risks of developme…
View article: Patient preferences regarding incidental genomic findings discovered during tumor profiling
Patient preferences regarding incidental genomic findings discovered during tumor profiling Open
BACKGROUND During the process of tumor profiling, there is the potential to detect germline variants. To the authors' knowledge, there currently is no accepted standard of care for how to deal with these incidental findings. The goal of th…
View article: Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools
Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools Open
Interpretation of complex cancer genome data, generated by tumor target profiling platforms, is key for the success of personalized cancer therapy. How to draw therapeutic conclusions from tumor profiling results is not standardized and ma…